Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.38 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1802687 | 0.88 | MEN1 (0.47) | KDM4CKMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL23835071 | 0.85 | KDM4C (0.46) | KDM4CKMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL6304989 | 0.83 | MEN1 (0.46) | KDM4CKMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL17176924 | 0.82 | KDM4C (0.45) | KDM4CKMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL6309376 | 0.80 | LTA4H (0.43) | KDM4CKMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL14334269 | 0.80 | KDM4E (0.39) | L3MBTL1NPC1ROCK2 | |
| SCHEMBL17077796 | 0.77 | KDM4C (0.43) | KDM4CKMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL3114026 | 0.77 | KDM4C (0.46) | KDM4CKMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL7466898 | 0.75 | KDM4C (0.53) | KDM4CKMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL5585308 | 0.75 | KDM4C (0.45) | KDM4CKMT2AMEN1L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949562-B2 | Heterocyclic compounds as ligands of the GABAA receptor | NEUROGEN CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | YOHANNES DANIEL (US) | 2004-06-10 | — | — | US | disclosed |
| US-6653471-B2 | Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction | NEUROGEN CORPORATION | 2003-11-25 | — | — | US | disclosed |
| EP-1325006-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR | NEUROGEN CORPORATION (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | PFIZER INC | 2003-06-05 | — | — | US | disclosed |
| WO-2002012442-A2 | HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR | NEUROGEN CORPORATION (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105081-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | KDM4C 2965/4885KMT2A 2120/4885MEN1 2641/4885 |
| US-20040110778-A1 | Heterocyclic compounds as ligands of the GABAA receptor | GABRB1, GABRP, GABRA1 | KDM4C 2965/4885KMT2A 2120/4885MEN1 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.